Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SUMO3 | P55854 | 1/20 | 0.32 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.32 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9363797 | 0.77 | TSHR (0.48) | CDK1CYP1A2 | |
| SCHEMBL2402013 | 0.76 | CDK2 (0.50) | INSRIGF1RFGFR1KDRHTR2A | |
| SCHEMBL16873181 | 0.75 | CYP3A4 (0.40) | ALDH1A1GAARAB9AKDM4EKMT2A | |
| SCHEMBL5934350 | 0.75 | HTT (0.40) | ALDH1A1KMT2AMEN1MAPK1LMNA | |
| SCHEMBL30850669 | 0.74 | CDK4 (0.35) | CDK1 | |
| SCHEMBL5184898 | 0.73 | ADORA3 (0.32) | ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL1019383 | 0.73 | IP6K1 (0.47) | ALDH1A1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL17099324 | 0.72 | XDH (0.43) | KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL8523000 | 0.72 | INSR (0.39) | INSRIGF1RFGFR1KDRHTR2A | |
| SCHEMBL4241034 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4096678-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-4088718-A1 | METHODS FOR TREATING CORONAVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220227776-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | Copycat Sciences Inc. (US) | 2022-07-21 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100234585-A1 | PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | PHARMASSET, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| EP-2227482-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | Pharmasset, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090318380-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009067409-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318380-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | HAVCR2, NUDT1, NT5C3B | INSR 3117/4885IGF1R 4200/4885FGFR1 4057/4885 |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | INSR 3208/4885IGF1R 4779/4885FGFR1 711/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | INSR 1536/4885IGF1R 2483/4885FGFR1 3620/4885 |
| US-20090036666-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | INSR 3208/4885IGF1R 4779/4885FGFR1 711/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | INSR 3009/4885IGF1R 4390/4885FGFR1 4169/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | INSR 3424/4885IGF1R 4488/4885FGFR1 2199/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | INSR 1653/4885IGF1R 4503/4885FGFR1 3226/4885 |
| US-20100234585-A1 | PREPARATION OF ALKYL-SUBSTITUTED 2-DEOXY-2-FLUORO-D-RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | NSUN2, FBL, UMPS | INSR 2866/4885IGF1R 4026/4885FGFR1 2540/4885 |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | INSR 3208/4885IGF1R 4779/4885FGFR1 711/4885 |
| US-20220227776-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | ACE2, ACE, PNP | INSR 2364/4885IGF1R 4658/4885FGFR1 2203/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | INSR 1653/4885IGF1R 4503/4885FGFR1 3226/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | INSR 1770/4885IGF1R 4644/4885FGFR1 1379/4885 |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | INSR 3208/4885IGF1R 4779/4885FGFR1 711/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | INSR 3084/4885IGF1R 4371/4885FGFR1 4142/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | INSR 4540/4885IGF1R 4802/4885FGFR1 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.